Received for publication July 28, 2004.
Revised October 7, 2004.
Accepted for publication October 7, 2004.

Ertiprotafib Improves Glycemic Control and Lowers Lipids Via Multiple Mechanisms

Abstract

Ertiprotafib belongs to a novel class of insulin sensitizers developed for treatment of type 2 diabetes. In insulin resistant rodent models, ertiprotafib and a close analog lowered both fasting blood glucose and insulin levels, and improved glycemic excursion during an oral glucose tolerance test. Additionally, treatment of rodents improved lipid profiles, with significantly lowered triglyceride and free fatty acid levels. These results suggested that this therapeutic activity might involve mechanisms in addition to PTP1b inhibition. Here, we demonstrate that ertiprotafib activates PPAR and PPAR at concentrations comparable to known agonists of these regulators. Furthermore, it is able to drive adipocyte differentiation of C3H10T_1/2 cells, a hallmark of PPAR activation. Livers from ertiprotafib treated animals showed significant induction of acyl-CoA oxidase activity, likely due to PPAR engagement in these animals. We also show that ertiprotafib inhibits PTP1b in vitro with non-classical kinetics at concentrations above its EC50s for PPAR agonism. Thus, the complete mechanism of action for ertiprotafib and related compounds in vivo may involve multiple independent mechanisms, including (but not necessarily limited to) PTP1b inhibition and dual PPAR/PPAR agonism. Ertiprotafib pharmacology and interpretation of clinical results must be seen in light of this complexity.

Key words: Insulin, PPARs